Trial · NCT02551744
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
NCT02551744, Not applicable, Completed, Kaohsiung Veterans General Hospital.; results first posted 2019-08-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers. Trials, record NCT02551744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02551744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
- NCT number
- NCT02551744
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 101 participants, actual
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Conditions
- Peptic Ulcer
- Interventions
- histamine-2 receptor antagonist group, proton pump inhibitor group
- First posted
- 2015-09-16
- Last updated
- 2019-08-08
- Results first posted
- 2019-08-08
- Limitations and caveats
- The trial was performed in a single country
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Ulcer Recurrence | six month | Follow-up endoscopy was performed at the end of the 6th month |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Ulcer Recurrence | six month | Intention to treat | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Ulcer Recurrence | Proton Pump Inhibitor Group | 1 | participants | ||
| Number of Participants With Ulcer Recurrence | Histamine-2 Receptor Antagonist Group | 7 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Proton Pump Inhibitor Group | 50 | |
| Overall Study | STARTED | Histamine-2 Receptor Antagonist Group | 51 | |
| Overall Study | COMPLETED | Proton Pump Inhibitor Group | 50 | |
| Overall Study | COMPLETED | Histamine-2 Receptor Antagonist Group | 51 | |
| Overall Study | NOT COMPLETED | Proton Pump Inhibitor Group | 0 | |
| Overall Study | NOT COMPLETED | Histamine-2 Receptor Antagonist Group | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | General disorders | Proton Pump Inhibitor Group | 1 | 50 | 1 |
| other | Abdominal pain | General disorders | Histamine-2 Receptor Antagonist Group | 1 | 51 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Proton Pump Inhibitor Group | 0 | 50 |
| Total, all-cause mortality | Histamine-2 Receptor Antagonist Group | 0 | 51 |
| Total, other adverse events | Proton Pump Inhibitor Group | 1 | 50 |
| Total, other adverse events | Histamine-2 Receptor Antagonist Group | 1 | 51 |
| Total, serious adverse events | Proton Pump Inhibitor Group | 0 | 50 |
| Total, serious adverse events | Histamine-2 Receptor Antagonist Group | 0 | 51 |
Source ClinicalTrials.gov
Papers21
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Proton Pump Inhibitor Group vs Histamine-2 Receptor Antagonist Group: Number of Participants With Ulcer Recurrence | Trial comparisons |
| Proton Pump Inhibitor Group vs Histamine-2 Receptor Antagonist Group: deaths from any cause | Trial comparisons |
| Proton Pump Inhibitor Group vs Histamine-2 Receptor Antagonist Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02551744
GET https://conductscience.org/api/trials/v1/NCT02551744/papers?page=2